Research Grade Sotigalimab
Product Sizes
1 mg
£506.00
DHD68911-1MG
5 mg
£1169.00
DHD68911-5MG
25 mg
£2865.00
DHD68911-25MG
About this Product
- SKU:
- DHD68911
- Additional Names:
- APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
- Buffer:
- 0.01M PBS, pH 7.4.
- translate.label.attr.clone:
- Sotigalimab
- Clonality:
- Recombinant Monoclonal
- Concentration:
- 1.7 mg/ml
- Extra Details:
- The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.
- Host:
- Human
- Immunogen:
- Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
- Isotype:
- IgG1, kappa
- Physical State:
- Liquid
- Purity:
- >95%
- Purification:
- Protein A/G purified from cell culture supernatant.
- Reactivities:
- Human
- Shipping Conditions:
- Blue Ice
- Source:
- XtenCHO
- Storage Conditions:
- -20[o]C Avoid freeze/thaw cycles., 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- AntibodySystem
- Type:
- Antibody: Recombinant Antibodies
- Manufacturer's Data Sheet:6515.html
